OraSure Technologies (OSUR) to Release Earnings on Wednesday

OraSure Technologies (NASDAQ:OSUR) is expected to be releasing its Q1 2026 results after the market closes on Wednesday, May 6th. Analysts expect OraSure Technologies to post earnings of ($0.16) per share and revenue of $27.7160 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Wednesday, May 6, 2026 at 5:00 PM ET.

OraSure Technologies (NASDAQ:OSUR) last released its earnings results on Wednesday, February 25th. The medical instruments supplier reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.02). The company had revenue of $26.76 million during the quarter, compared to analysts’ expectations of $26.44 million. OraSure Technologies had a negative net margin of 59.76% and a negative return on equity of 16.45%.

OraSure Technologies Price Performance

OSUR opened at $2.95 on Tuesday. The stock has a market cap of $212.31 million, a price-to-earnings ratio of -3.17 and a beta of 0.89. OraSure Technologies has a twelve month low of $2.08 and a twelve month high of $3.82. The company’s 50-day moving average price is $3.04 and its two-hundred day moving average price is $2.76.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (d)” rating on shares of OraSure Technologies in a research note on Thursday, January 22nd. Two equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, OraSure Technologies presently has an average rating of “Reduce” and an average target price of $3.00.

Insider Buying and Selling

In other OraSure Technologies news, CEO Manner Carrie Eglinton purchased 32,300 shares of the company’s stock in a transaction that occurred on Friday, March 20th. The shares were bought at an average cost of $2.93 per share, for a total transaction of $94,639.00. Following the purchase, the chief executive officer owned 2,190,874 shares of the company’s stock, valued at $6,419,260.82. This represents a 1.50% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Kenneth J. Mcgrath purchased 32,300 shares of the company’s stock in a transaction that occurred on Friday, March 20th. The shares were acquired at an average price of $2.93 per share, for a total transaction of $94,639.00. Following the completion of the purchase, the chief financial officer directly owned 589,562 shares in the company, valued at $1,727,416.66. This represents a 5.80% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased a total of 108,643 shares of company stock worth $321,407 over the last 90 days. 3.90% of the stock is currently owned by corporate insiders.

Institutional Trading of OraSure Technologies

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Sei Investments Co. increased its holdings in OraSure Technologies by 16.4% during the 3rd quarter. Sei Investments Co. now owns 32,244 shares of the medical instruments supplier’s stock worth $103,000 after acquiring an additional 4,536 shares during the period. Russell Investments Group Ltd. increased its holdings in OraSure Technologies by 13.3% during the 4th quarter. Russell Investments Group Ltd. now owns 43,636 shares of the medical instruments supplier’s stock worth $106,000 after acquiring an additional 5,138 shares during the period. BNP Paribas Financial Markets increased its holdings in OraSure Technologies by 102.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 15,275 shares of the medical instruments supplier’s stock worth $49,000 after acquiring an additional 7,720 shares during the period. Envestnet Asset Management Inc. increased its holdings in OraSure Technologies by 32.7% during the 2nd quarter. Envestnet Asset Management Inc. now owns 33,018 shares of the medical instruments supplier’s stock worth $99,000 after acquiring an additional 8,133 shares during the period. Finally, Prudential Financial Inc. bought a new stake in OraSure Technologies during the 2nd quarter worth approximately $31,000. Institutional investors own 93.50% of the company’s stock.

OraSure Technologies Company Profile

OraSure Technologies, Inc is a Bethlehem, Pennsylvania–based diagnostic and medical device company specializing in the development, manufacture and commercialization of point-of-care and self-testing products. Founded in 1988, OraSure has built a portfolio of oral fluid and other non-invasive specimen collection technologies that support the detection of infectious diseases, drugs of abuse, and health and wellness biomarkers.

The company’s flagship product, the OraQuick® rapid HIV test, was the first Food and Drug Administration–approved over-the-counter oral fluid test for the detection of HIV-1/2 antibodies.